Anatoly Dritschilo

Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD.

Georgetown University Hospital provides healthcare services. Its services include cancer care, blood cancer, leukemia and myelodysplastic syndromes. The company is headquartered in Washington, DC.

Georgetown Lombardi Comprehensive Cancer Center is a comprehensive cancer center designated by the National Cancer Institute (NCI) and is a part of Georgetown University Medical Center. It is located in Washington, D.C. and is supported in part by a National Cancer Institute Cancer Center Support Grant. It is the only comprehensive cancer center in the area and serves as the research engine for MedStar Health, Georgetown University’s clinical partner. Georgetown Lombardi seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic, translational, and clinical research, patient care, and community education and outreach. Georgetown Lombardi also offers a master’s degree program in cancer biology, prevention, and control in partnership with the University of the District of Columbia (UDC).

Georgetown University Hospital provides healthcare services. Its services include cancer care, blood cancer, leukemia and myelodysplastic syndromes. The company is headquartered in Washington, DC.

NeoPharm, Inc. engages in the research, development, and commercialization of drugs for the treatment of various cancers and other diseases. The company has built its drug development program around two proprietary technology platforms, a tumor-targeting toxin platform which includes development for a new indication of Pulmonary Fibrosis, and a novel NeoLipid liposomal drug delivery system. It has advanced five drug product candidates in various stages of clinical and pre clinical development for the treatment of cancer and one drug product candidate in pre-clinical development for treatment of interstitial pulmonary fibrosis and asthma. NeoPharm was founded in May 15, 1900and is headquartered in Lake Bluff, IL.